Establishing Prospective Mediastinal Tumor Database of PUMCH

NCT06421805 | Recruiting

• 1 other identifier: MTDPUMCH
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to prospectively document the population characteristics, imaging findings, pathological features, prognostic factors, etc., of patients with mediastinal tumors. Clinical information will be structured and processed, and it is recommended to establish a mediastinal tumors database at Peking Union Medical College Hospital. The goal is to provide support for the quality of diagnosis and treatment, clinical protocols, and medical decision-making related to mediastinal tumors.

Conditions

Thymic Epithelial Tumor; Teratoma; Thymic Cyst; Retrosternal Goitre; Germ Cell Tumor; Lymphoma; Schwannoma

Keywords

mediastinal tumors; database; thymic epithelial tumor

Outcome Measures

Primary Outcomes (1)

• Overall survival (OS)

  Overall survival of patients with mediastinal tumors

  From date of enrollment until the date of death from any cause, assessed up to 20 years

Secondary Outcomes (1)

• Progression free survival (PFS)

  From date of enrollment until the date of first documented progression, assessed up to 20 years

Study Arms (8)

thymoma

mediastinal tumors\_thymoma

teratoma

mediastinal tumors\_teratomas

germ cell tumor

mediastinal tumors\_germ cell tumors

lymphoma

mediastinal tumor\_lymphoma

mediastinal neuroendocrine tumors (NETs)

mediastinal tumor\_NETs, including neuroendocrine tumours and neuroendocrine carcinomas.

neurinoma

mediastinal tumor\_neurinoma

thymic carcinoma

mediastinal tumor\_thymic carcinoma

others

mediastinal tumors\_other tumors

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients diagnosed with mediastinal tumors clinically or pathologically.

You may qualify if:

• Clinical or pathological diagnosis of mediastinal tumors;
• Written consent is able to obtained.

You may not qualify if:

• \. Incomplete clinicopathological information.

Sponsors & Collaborators

• Peking Union Medical College Hospital: lead

Study Sites (1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

After obtaining informed consent from the patients, tumor tissue specimens will be stored in the sample repository of PUMCH at -80 degrees Celsius.

MeSH Terms

Conditions

Thymic epithelial tumor; Teratoma; Mediastinal Cyst; Goiter, Substernal; Neoplasms, Germ Cell and Embryonal; Lymphoma; Neurilemmoma

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Cysts; Mediastinal Diseases; Thoracic Diseases; Respiratory Tract Diseases; Goiter; Thyroid Diseases; Endocrine System Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Neuroendocrine Tumors; Neuroectodermal Tumors; Neuroma; Nerve Sheath Neoplasms; Neoplasms, Nerve Tissue

Study Officials

• Shanqing Li, Prof.

  Peking Union Medical College Hospital

  STUDY CHAIR

Central Study Contacts

Xuehan Gao, MD

CONTACT

+86 18801341299; gaoxh1299@163.com

Yeye Chen, MD

CONTACT

13671338819; chenyeye@pumch.cn

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 20 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: April 20, 2024
• First Posted: May 20, 2024
• Study Start: January 1, 2012
• Primary Completion (Estimated): December 30, 2044
• Study Completion (Estimated): December 30, 2045
• Last Updated: May 20, 2024

Record last verified: 2024-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)